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NOVEL APPROACH FOR PREDICTING GVHD REACTIVE T CELLS USING
V SPECTRATYPE ANALYSIS OF DIVIDING CFSE-LABELED T CELLS
FROM A MIXED LYMPHOCYTE REACTION
Zilberberg, J.1, Fanning, S.L.1, Friedman, T.M.1, Korngold, R.1
1Hackensack University Medical Center, Hackensack, NJ.
The major complication associated with allogeneic hematopoi-
etic stem cell transplantation (HSCT) is graft-versus-host disease
(GVHD), which is mediated by mature T cells in the donor
transplant inoculum. Since donor T cells are also important in
preventing graft failure, opportunistic infections and leukemia re-
lapses after transplant, it would be highly advantageous to identify
and separate T cells with GVHD-reactivity from those capable of
mediating graft-versus-leukemia (GVL) responses. In this regard,
TCR V repertoire analysis by CDR3-size spectratyping can be a
powerful tool to characterize alloreactive T cell responses. As an
initial test of this capability, we studied lethal GVHD in the B6 -
CXB-2 MHC-matched, minor histocompatibility antigen dispar-
ate murine model to determine the correlation between the in vitro
detected alloreactive B6 CD8 T cell responses and their actual
involvement in the development of GVHD upon transfer to le-
thally irradiated CXB-2 recipients. Previous methods to obtain the
V repertoire from responding mixed lymphocyte reactions
(MLR) required expansion of the alloreactive cells in secondary
stimulation cultures, for a total of 20 days. To signiﬁcantly shorten
this incubation period, in order to eventually adapt this technique
for clinical use, we used the ﬂuorescent-based intracellular dye
CFSE to label responding cells in a 4-day MLR and ﬂuorescent
cell sorting to isolate the divided alloreactive cells that could then
be processed for V spectratype analysis. In a comparative study of
the predictive value of the V repertoire detected in traditional
MLR versus CFSE/MLR, the results indicated that the former
approach correlated with 78% of the V CDR3-size skewing
patterns observed in mice with B6 - CXB-2 GVHD, and the
CFSE/MLR approach corresponded to 65% of those skewed V
families found in vivo. These results suggest that in vitro spectra-
typing analysis, and particularly the use of CFSE to predict in vivo
reactivity, may be a useful technique in eventually guiding the
manipulation of the donor T cell inoculum in order to improve the
outcome of HSCT.
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DENDRITIC CELL VACCINATION EXPANDS ANTIGEN SPECIFIC T CELLS
FOLLOWING ALLOGENEIC TRANSPLANTATION
Herby, S.1, Davis, J.1, Wayne, A.S.1, Fry, T.J.1 1Pediatric Oncology
Branch, CCR, NCI, NIH, Bethesda, MD.
Background: The graft versus malignancy (GVM) effect after
allogeneic hematopoietic stem cell transplantation (alloHSCT) is
the most potent form of cancer immunotherapy. However, disease
recurrence remains a major contributor to poor outcome and
non-speciﬁc strategies to enhance GVM responses are frequently
complicated by GVHD. Dendritic cell (DC) vaccines may be a
strategy to increase the potency and speciﬁcity GVM responses but
the impact of alloreactivity on DC vaccine responses has not been
established. Methods: We tested DC vaccines in a parent
(C57BL/6) into F1 (C57BL/6xC3H.SW) MHC-matched T cell-
depleted (TCD) transplant. Female recipients received donor lym-
phocytes (DLI) with a DC vaccine targeting the male antigenic
complex (HY) on days 14 and 28. Responses were measured using
ELISPOT and MHC class I tetramer on day 42. Results: Mice
receiving TCD bone marrow with low dose of DLI (1106) show
no GVHD-associated weight loss. Higher dose DLI (5-20106)
induces weight loss without lethality. DC vaccination of allogeneic
recipients plus low dose DLI generates quantitatively similar dom-
inant CD8 and CD4 vaccine responses to syngeneic controls with
increased subdominant CD8 responses (15104 vs 7104 cells/
spleen, p0.06). GVHD induction with higher doses of DLI
results in loss of vaccine responses. We next explored whether
responses can be generated in the absence of thymic T cell regen-
eration since this pathway may be limited following alloHSCT.
Equivalent HY responses to thymus-bearing recipients are gener-
ated in syngeneic, thymectomized recipients but requires high dose
(20106) DLI as a source for peripheral expansion. Allogeneic
recipients receiving high dose DLI are unable to respond to HY
vaccination due to GVHD. 10106 8-methoxypsoralen and ultra-
violet B light-induced apoptotic donor- or recipient-type spleeno-
cytes infused at the time of DLI (to model extracorporeal photo-
pheresis (ECP)) prevents GVHD even in mice receiving high dose
DLI. Importantly, modulation of GVHD by ECP preserves vac-
cine-mediated HY responses even in recipients lacking a thymus.
Conclusions: DC vaccines can expand antigen-speciﬁc T cells
following alloHSCT. GVHD adversely affects these responses and
precludes the induction of DC vaccine responses in the absence of
thymic function. Modulation of GVHD by ECP preserves vaccine
responses to non-alloantigens. This approach may provide an op-
portunity to selectively enhance graft versus tumor responses fol-
lowing alloHSCT.
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RISK FACTORS ASSOCIATED WITH CHRONIC GVHD REVISITED: A
STUDY OF 142 PATIENTS WITH MALIGNANT DISEASES TRANS-
PLANTED IN A SINGLE CENTER IN BRAZIL
Funke, V.A.M.1, Medeiros, L.1, Coutinho, E.N.1, Pettengil, C.1,
Ruiz, J.1, Oliveira, M.M.1, Setubal, D.C.1, Bonﬁm, C.M.1,
Bitencourt, M.A.1, Zanis-Neto, J.1, de Medeiros, C.P.1, Pasquini, R.1
1Hospital de Clinicas - Universidade Federal do Parana, Curitiba, PR,
Brazil.
Chronic graft-versus-host disease is a well known cause of trans-
plant related mortality after HSCT. OBJECTIVE: evaluate the
impact chronic GVHD at the overall survival and disease free
survival among 142 patients who received transplants for malignant
diseases and developed chronic graft-versus-host-disease from
07/95 to 06/05 at the BMT center of HC-UFPR in Curitiba,
Brazil. PATIENTS CHARACTHERISTICS: male: 94; female:
48; median age 31 years (range: 1-54). Cell source was bone
marrow in 134 patients, cord blood in four patients and pheriph-
eral blood in four patients. Conditioning regimen was nomyeloa-
blative in 3 patients and conventional in 139 patients. Immunepro-
phylaxis: CSA  MTX  CTC  76; CSAMTX 54; CSA
without MTX /- CTC 8 patients. HLA compatible: 120 pa-
tients, mismatch class I : 10, class II : 6, more than one mismatch
: 2. Thirty three patients received HSCT from unrelated donors,
11 from related alternative donors and 98 from siblings. Female
donor / male recipient in 47 patients. Median duration of disease:
31 months. Diagnosis: CML 79, AML/MDS 44; ALL 15, OTH-
ERS 4.
RESULTS: Overall survival was 67% in 10 years. Median sur-
vival 2181 dias (82-4575). Risk factors with signiﬁcance for survival
were Platelets less than 100,000 /mm3 at diagnosis, and lympho-
cytes less than 1,500/mm3. There was a tendency for TB more
than 1.2 at diagnosis. There was no signiﬁcance for age, gender,
presence of female donor/male patient or HLA compatibility.
CONCLUSIONS: This study conﬁrmed previous data and
identiﬁed thrombocytopenia and lymphopenia at the diagnosis as
risk factors for survival in patients with chronic graft-versus-host
disease.
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ALEMTUZUMAB IN THE TREATMENT OF STEROID REFRACTORY ACUTE
GRAFT-VERSUS-HOST DISEASE
Gomez-Almaguer, D.1, Ruiz-Arguelles, G.2, Gonzalez-Llano, O.1,
Gutierrez, C.1, Jaime-Perez, J.C.1, Tarin-Arzaga, L.1, Giralt, S.3
1Hospital Universitario, Monterrey, NL, Mexico; 2Centro de Hemato-
logia y Medicina Interna de Puebla, Puebla, Mexico; 3MD Anderson
Cancer Center, Houston, TX.
Corticosteroids therapy is the mainstay of treatment for GVHD,
however, it heavily impacts on post transplant morbidity and new
modalities are continually needed. Alemtuzumab a humanized
monoclonal antibody to CD52 has been used mainly as GVHD
prophylaxis. Only a few patients have been treated with this anti-
body. From December 2004 to May 2006, we recruited 13 steroid
refractory grade II-IV acute GvHD patients in a prospective trial
evaluating the efﬁcacy of alemtuzumab (Campath 1H) after exclu-
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sion of other severe HST-related complications. Primary end-
points were response to treatment after 14 and 28 days. Secondary
endpoints were side effects and incidence of infectious complica-
tions. Treatment consisted of Campath 1H 10mg given s.c. on days
1-5. Median age was 33 years old (range:1-59) years, a ﬂudarabine-
based reduce intensive conditioning (RIC) regimen was used and
the hematopoietic cells were obtained from HLA-identical siblings
in 12 cases and one patient received stem cell from umbilical cord
blood. All but one received CSA and MTX for GvHD prophylaxis.
GvHD was classiﬁed as grade II in 5 patients, III in 6 and IV in 2;
predominant organ affected was gut in 6 cases, skin in 7, liver in 4
and combination of gut and skin in 4 patients. In 6 of the 13
patients the clinical manifestations of GVHD were noticed after
the ﬁrst 100 days of HSCT. Complete resolution of GvHD, partial
response and no response were seen respectively in 23%, 62% and
15%. Six over the 13 patients were able to decrease steroid use.
Five patients developed CMV (pp65) reactivation and 3 of them
were successfully treated with valganciclovir. All patients main-
tained complete chimerism during and after alemtuzumab therapy,
and after a median follow-up of 5 months (range, 1- 18months), 8
remain alive, 3 without evidence of GVHD. Five patients died, 3
due to GvHD and the others due to infectious complications. This
preliminary study suggests that alemtuzumab is a well-tolerated
agent and has a beneﬁcial effect in the treatment of refractory
GvHD. It is only a pilot study and more studies are needed, but we
suggest that this modality could be used early in the management
of these patients in order to improve quality of life and reduce the
long-term side effects of corticosteroids.
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GRAFT VERSUS HOST DISEASE AFTER STEM CELL ALLOTRANSPLANTA-
TION WITH LOW DOSE TBI, FLUDARABINE AND ATG
Grosskreutz, C.L.1, Scigliano, E.1, Osman, K.1, Isola, L.M.1 1Mount
Sinai Medical Center, New York, NY.
We previously showed that antithymocyte globuline (ATG)
given with TBI 200 cGy and ﬂudarabine results in high rate of
donor engraftment. Its inﬂuence on acute and chronic graft versus
host disease (GVHD) and on graft versus tumor effect is less
known. The reported rates of acute, grade II-IV GVHD after
non-myeloablative stem cell transplantation (NST) have ranged
from 20% to 58%. In the setting of NST, advanced recipient
and/or donor ages increase the risk of GVHD. In addition, treat-
ment of GVHD with high doses of corticosteroids is poorly tol-
erated in older adults. For these reasons, strategies to decrease the
incidence and severity of GVHD in NST are needed. Sixty-ﬁve
patients underwent non myeloablative stem cell transplant using
ATG horse derived 15mg/kg/day x 4 days or rabbit derived 1.5
mg/kg/day x 4 doses on days -4 to -1, TBI 200 cGy in a single
fraction given on day -5 and ﬂudarabine 30mg/m2/day x 3 doses on
days -4 to -2. Mycophenolate mofetil (MMF) 15mg/kg twice daily
and cyclosporine (CSA) 6 mg/kg twice daily were started on day -5
for GVHD prophylaxis. Patients characteristics is summarized in
Table 1. Between 30 to 60 days post transplant peak donor chi-
merism 80% was documented in 54 patients (93%) and 50-80%
donor chimerism in 4 pts (7%). At a median follow up of 862 days,
24 patients (37%) developed GVHD. The median age of the
patients with and without GVHD was 56 years respectively. Acute
GVHD (aGVHD) grade II-IV developed in 19 pts (29%). Fatal
GVHD of liver and/or gut occurred in nine pts (14%). Forty one
patients survived more than 100 days. Five patients (12%) had
chronic GVHD (cGVHD), two had extensive and three limited
involvement. Relapsed disease was observed in 22 patients (34%).
Relapsed disease was the main cause of death in patients with AML
9/13 (69%). Six patients with AML had relapsed/refractory disease
at the time of transplant. Relapse rate for patients with NHL was
29% and 33% for those with MM. Sixteen patients (25%) are alive
in CR (10 NHL and 3 MM and 3 MDS/MPD), with a median
follow up of 862 days. Infections occurred in 15 patients (23%) and
were fatal in 13 (20%). Our study conﬁrms the usefulness of ATG
in the prevention of acute and chronic graft-versus-host disease
after NST. Except for some caveats related to donor type, we were
not able to demonstrate a major impact in the rate of grade III and
IV aGVHD owing to the use of ATG. The best transplant out-
comes were seen in patients with lymphoid malignancies.
Table 1: Patients Characteristics
N 65
Age (median/range) 56 (19-71)
Male/Female 41/24
Donor
Age (median/range) 48 (20-71)
Male/Female 33/32
Matched related 42 (65%)
Matched unrelated 18 (28%)
Mismatch related 1 (1.5%)
Mismatch unrelated 4 (6%)
Female donor/Male recipient 20 (31%)
Diagnosis (%)
NHL 21 (32%)
MM 15 (23%)
AML 13 (20%)
MDS 4 (6%)
MPD 4 (6%)
ALL 2 (3%)
CLL 2 (3%)
PNH/SAA 2 (3%)
HD 1 (1.5%)
CML 1 (1.5%)
Stem cell source (%)
G-PBPC 58 (89%)
Marrow 7 (11%)
Prior ASCTx (%) 11 (17%)
Median follow up for patients alive 862 days
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ETANERCEPT AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-
HOST DISEASE
Gulbis, A.M.1, Hsu, Y.1, Neumann, J.L.1, Hymes, S.1, de Lima, M.J.1,
Hosing, C.M.1, Khouri, I.F.1, Qazilbash, M.H.1, Kebriaei, P.1,
Andersson, B.S.1, Champlin, R.E.1, Couriel, D.P.1 1University of Texas
M.D. Anderson Cancer Center, Houston, TX.
Objective: To assess the activity and toxicity of etanercept in the
salvage treatment of patients with chronic graft versus host disease
(cGVHD) failing steroids or further therapy. Patients/Methods:
Retrospective study of all patients with moderate to severe
cGVHD seen in our GVHD clinic from 11/2004 to 11/2005, who
received etanercept for the treatment of cGVHD. The diagnosis
and staging of cGVHD was based on NIH Consensus criteria. All
patients were either steroid refractory (progressive disease (PD),
stable disease (SD) or partial response (PR) despite prolonged
treatment with steroids) or steroid dependent (ﬂaring after steroid
discontinuation). Results: We identiﬁed a total of 9 patients
treated with etanercept. Organs involved included: skin (n7, 6
with sclerosis), lung (n1), eye (n3) and mouth (n1). Four
patients had involvement of cGVHD in more than 1 organ site. All
patients receive salvage with other agents in addition to steroids
prior to receiving etanercept. Seven received sirolimus, 7 received
extracorporeal photopheresis (ECP), 2 received mycophenolate
mofetil, 1 received inﬂiximab, 2 received hydroxychloroquine, and
1 received thalidomide. At initiation of etanercept, 7 patients were
on steroids, 6 patients continued ECP and 3 patients continued
multi-drug salvage regimens. Patients received etanercept 50 mg
subcutaneously (SC) weekly. Only 1 patient had a reduction in dose
to 50 mg SC every other week when response was noted. Overall
response rate was 56 % (5/9). Three of 6 patients with sclerosis had
a response, one was a complete response and 2 had a PR. The
patient with lung cGVHD had a PR and the patient cGVHD of the
mouth had a PR. Patients received between 4 to 80 doses (4
patients received greater then 20 doses) of etanercept 50 mg SC
weekly. Five of the seven patients on corticosteroids were able to
taper within one month of starting etanercept. The patient with
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